GlaxoSmithKline Pharma Reports 16% Profit Growth in September Quarter
On Tuesday, GlaxoSmithKline Pharmaceuticals (GSK) informed that its net profit grew by 16% in the July-September quarter, going ₹252 crore. This growth was driven by strong sales across various products. In the same period last year, the company documented a profit of ₹217 crore.
GSK’s revenue from functions also went up, reaching ₹1,010 crore this quarter compared to ₹957 crore a year ago.
To celebrate its 100 years in India, the company’s board announced a special interim dividend of ₹12 per share. Managing Director Bhushan Akshikar said the business is committed to growth and invention.
The company’s popular brands performed well:
- Augmentin remained the top-selling brand in the Indian pharmaceutical market.
- The respiratory product portfolio, including Nucala and Trelegy, gained more market allocation.
- Vaccines for children earned double-digit growth and continued to lead the private market.
- In the adult vaccines segment, GSK’s Shingrix vaccine for shingles gained speed with creative marketing strategies.
However, despite the good financial performance, GSK’s stock price closed negligibly lower, down 0.68% at ₹2,624.50 on the Bombay Stock Exchange.
